glp-1 news today cardiovascular outcomes 2025 november studies add to growing body of evidence demonstrating significant benefit on What Ozempic and other GLP-1

After TGF signalling inhibition in the high-glucose group, -SMA expression was significantly reduced to an undetectable level (Fig

The PA criteria differ by diagnosis: For Type 2 diabetes indication: Documented Type 2 diabetes diagnosis (A1C 6.5% or fasting glucose 126 mg/dL) BMI 27 kg/m (this requirement appears in most UnitedHealthcare medical policies even for diabetes, though not an FDA requirement) Trial and failure of metformin for at least 90 days, unless contraindicated Trial and failure of at least one other oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days A1C remains 7.0% despite conventional therapy For obesity indication (when covered): BMI 30 kg/m, or BMI 27 kg/m with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) Documented weight-loss attempts with behavioral modification and diet for at least 6 months No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2) Prescriber must be MD, DO, NP, or PA (some plans require endocrinologist or bariatric specialist) The PA approval timeline is 3 to 7 business days for standard requests, 24 hours for urgent requests

First, lets back up and cover a few basics: Short for nicotinamide adenine dinucleotide, NAD is a coenzyme found in every cell of the body

104 Clinically, it is well established that weight loss and physical activity can reduce insulin levels by 1030%, and that lowering of insulin by 25% may be associated with a 5% absolute improvement in breast cancer mortality